Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)
Completed · Phase 2 · NCT04295538
Conditions: Spinal Cord Injury (SCI)
At a glance
- Research payments reported, 2025
- $157,578
- U.S. investigators named
- 12
- Sites paid
- 18
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- AbbVie
- Tested
- Elezanumab (drug), Placebo (drug)
- Dates
- Started 2020-09-06; completion 2026-01-26
- Results posted
- Not yet
Acute Spinal Cord Injury (SCI) is a rare injury that leads to permanent neuromotor impairment and sudden disability. Approximately 25,000 people experience cervical SCI in the United States, Europe, and Japan every year. The purpose of this study is to see if elezanumab is safe and assess change in Upper Extremity Motor Score (UEMS) in participants with acute traumatic cervical SCI. Elezanumab is an investigational drug being developed for the treatment of SCI. Elezanumab is a monoclonal antibody, that binds to an inhibitor of neuronal regeneration and neutralizes the inhibitor, thus potentially promoting neuroregeneration. This study is "double-blinded", which means that neither trial pa…
From ClinicalTrials.gov, last updated 2026-02-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $157,578 in research payments for this study in 2025 (57 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Kee D. Kim, M.D. Neurosurgery · Sacramento, CA
- Saman Shabani Neurosurgery · Orange, CA
- Aruna Ganju, MD Neurosurgery · Chicago, IL
- Muhammad M. Abd-el-barr, M.D., PH.D. Neurosurgery · Boston, MA
- Wilson Z. Ray, MD Neurosurgery · Saint Louis, MO
- Nasim Ahmed, MD General Surgery · Neptune, NJ
- Mohammed F. Khan, M.D. Neurosurgery · Oradell, NJ
- Dana E. Adkins JR., M.D. Neurosurgery · Valhalla, NY
- Won Hyung Ryu, MD Neurosurgery · Portland, OR
- James S. Harrop, M.D. Neurosurgery · Philadelphia, PA
- Brian Cameron, MD Neurosurgery · Richmond, VA
- Chun-po Yen, M.D. Neurosurgery · Charlottesville, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Virginia Commonwealth University $40,815
- $26,000
- Duke University $17,597
- University of California Davis Medical Center, CA $16,955
- Sentara Leigh Hospital, VA $16,048
- Northwestern University $12,700
- Jfk University Medical Center, NJ $6,850
- Medical College of Wisconsin $4,474
- Ohsu Hospital and Clinics, OR $3,853
- Washington University in St Louis $2,207
- Thomas Jefferson University $2,107
- University of Virginia Medical Center, VA $1,833
- Hackensack University Medical Center, NJ $1,473
- Virginia Commonwealth University School of Medicine $1,000
- Jersey Shore University Medical Center, NJ $1,000
- Sentara Norfolk General Hospital, VA $917
- Sidney Kimmel Medical College at Thomas Jefferson University $750
- Medical College of Wisconsin Medical School $667
- Northwestern University Health Service Evanston $333
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.